FDA panel criticizes agency approval of controversial $56,000 Alzheimer’s drug

The advisory panel that reviewed the controversial and expensive Alzheimer’s disease drug Aduhelm criticized the Food and Drug Administration for approving it, saying that the agency used a standard not supported by evidence. The advisory committee, known as the Peripheral and Central Nervous System Advisory Committee, examined the evidence for Aduhelm in November 2020 and… Read More »

‘New GSK’ shows strength amid investor pressure, but Shingrix still needs to regain its footing

As activist investor Elliott Management turns up the heat on GlaxoSmithKline, CEO Emma Walmsley’s new vision for the company is showing strength. But while Glaxo’s vaccines business does gangbusters overall, its crown jewel Shingrix has yet to hit its stride after the pandemic knocked it off its course. GSK’s shingles vaccine reeled in £295 million… Read More »

Latest snapshot of the coronavirus impact

LATEST COVID-19 DEVELOPMENTS: * NSW recorded 177 new COVID-19 cases and a death on Wednesday, as Premier Gladys Berejiklian confirmed lockdown will be extended until at least August 28 for Greater Sydney, the Central Coast, the Blue Mountains, Wollongong and Shellharbour. * Some restrictions have changed, including the introduction of a singles bubble for those… Read More »